Profile data is unavailable for this security.
About the company
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
- Revenue in USD (TTM)2.49m
- Net income in USD-96.21m
- Incorporated2016
- Employees255.00
- LocationSingular Genomics Systems Inc3010 SCIENCE PARK ROADSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 333-7830
- Fax+1 (302) 531-3150
- Websitehttps://singulargenomics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 19.13m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -38.25m | 19.32m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -2.42m | 19.45m | 7.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.042 | 0.00 | -- | -- | 0.00 | -97.97 | -- | -- | -- | -- | -- | -- | -- | -- | -25.68 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -21.14m | 19.50m | 29.00 | -- | 2.25 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Goldenwell Biotech Inc | 1.08k | -114.27k | 19.80m | -- | -- | 368.37 | -- | 18,333.33 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 19.87m | 46.00 | -- | 0.8474 | -- | 0.4855 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| GlycoMimetics Inc | 10.00k | -37.28m | 20.00m | 35.00 | -- | 0.6918 | -- | 2,000.33 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 20.01m | 255.00 | -- | 0.1276 | -- | 8.03 | -39.39 | -39.39 | 1.02 | 63.47 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Synlogic Inc | 3.21m | -73.22m | 20.02m | 6.00 | -- | 1.49 | -- | 6.25 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| AIM ImmunoTech Inc | 193.00k | -31.12m | 20.13m | 26.00 | -- | 4.28 | -- | 104.30 | -0.637 | -0.637 | 0.004 | 0.096 | 0.0072 | -- | 0.2189 | 7,423.08 | -116.00 | -45.64 | -148.40 | -48.35 | 74.09 | -231.75 | -16,123.32 | -11,695.01 | -- | -- | 0.3478 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -19.34m | 20.19m | 20.00 | -- | -- | -- | -- | -26.80 | -26.80 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -72.94 | -- | -92.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.39 | -- | -- | -- |
| Carmell Corp | 0.00 | -18.29m | 20.57m | 9.00 | -- | -- | -- | -- | -1.58 | -1.49 | 0.00 | -0.0719 | 0.00 | -- | -- | 0.00 | -428.46 | -- | -- | -- | 58.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -35.58m | 20.81m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -0.3734 | 0.00 | -- | -- | 0.00 | -91.54 | -118.12 | -136.45 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.44 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 20.90m | 27.00 | -- | 0.9115 | -- | 18.15 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Aprea Therapeutics Inc | 963.81k | -12.72m | 21.01m | 7.00 | -- | 0.7266 | -- | 21.80 | -3.32 | -3.32 | 0.2503 | 5.57 | 0.0296 | -- | -- | 137,687.10 | -39.00 | -68.66 | -43.83 | -77.19 | -- | -- | -1,319.45 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
Data as of Jul 25 2024. Currency figures normalised to Singular Genomics Systems Inc's reporting currency: US Dollar USD
23.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deerfield Management Co. LPas of 09 Aug 2023 | 179.55k | 7.27% |
| QVIDTVM Management LLCas of 31 Mar 2024 | 83.56k | 3.38% |
| UBS Securities LLCas of 31 Mar 2024 | 73.65k | 2.98% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 70.90k | 2.87% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 61.86k | 2.51% |
| Casdin Capital LLCas of 31 Mar 2024 | 44.13k | 1.79% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 19.38k | 0.79% |
| Hightower Advisors LLCas of 31 Mar 2024 | 17.61k | 0.71% |
| Verition Fund Management LLCas of 31 Mar 2024 | 16.67k | 0.68% |
| Geode Capital Management LLCas of 31 Mar 2024 | 15.35k | 0.62% |
More ▼
Data from 31 Mar 2024 - 15 May 2024Source: FactSet Research Systems Inc.
